Michael Severino named Sarepta CEO as Douglas Ingram steps down

Sarepta appointed Michael Severino as Chief Executive Officer effective July 28, 2026, as Douglas Ingram departs the CEO post and the board.Original SEC Filing: Sarepta Therapeutics, Inc. [ SRPT ] - 8-K - Jul. 27, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying im…

Sarepta appointed Michael Severino as Chief Executive Officer effective July 28, 2026, as Douglas Ingram departs the CEO post and the board.

IndividualMichael Severino, M.D.Douglas Ingram

RoleChief Executive Officer; Class I Director (to serve until 2028 annual meeting)Chief Executive Officer; Board member

Type of ChangeAppointedDeparted

Effective DateJuly 28, 2026July 28, 2026

ReasonNot disclosedNot disclosed

Replacement InfoN/ASucceeded by Michael Severino

Background DetailsFormer CEO of Tessera Therapeutics and CEO‑Partner at Flagship Pioneering (Jun 2022–Jul 2026); former Vice Chairman & President and Chief Scientific Officer at AbbVie; senior roles at Amgen; M.D. Johns Hopkins; boards: Viatris (committee roles) and Avantor.Entered Consulting Agreement to serve as consultant through Dec 31, 2026 for $15,000 monthly.

Board/Committee Role ChangesAppointed Class I director (term until 2028 annual meeting)Departed as board member

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.